# Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent

> **NCT02660047** · PHASE4 · COMPLETED · sponsor: **Leiden University Medical Center** · enrollment: 51 (actual)

## Conditions studied

- Diabetes Mellitus Type 2
- Metabolic Syndrome
- Cardiovascular Disease
- Diastolic Dysfunction
- Fatty Liver

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Liraglutide - Placebo

## Key facts

- **NCT ID:** NCT02660047
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-03-09
- **Final completion:** 2018-03-09
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2018-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02660047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02660047, "Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02660047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*